{"product_id":"lead-optimization-for-medicinal-chemists-pharmacokinetic-properties-of-functional-groups-and-organic-compounds-9783527332267","title":"Lead Optimization for Medicinal Chemists:","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eSmall structural modifications can significantly affect the pharmacokinetic properties of drug candidates. This book, written by a medicinal chemist for medicinal chemists, is a comprehensive guide to the pharmacokinetic impact of functional groups, the pharmacokinetic optimization of drug leads, and an exhaustive collection of pharmacokinetic data, arranged according to the structure of the drug, not its target or indication. The historical origins of most drug classes and general aspects of modern drug discovery and development are also discussed. The index contains all the drug names and synonyms to facilitate the location of any drug or functional group in the book.\u003cbr\u003eThis compact working guide provides a wealth of information on the ways small structural modifications affect the pharmacokinetic properties of organic compounds, and offers plentiful, fact-based inspiration for the development of new drugs. This book is mainly aimed at medicinal chemists, but may also be of interest to graduate students in chemical or pharmaceutical sciences, preparing themselves for a job in the pharmaceutical industry, and to healthcare professionals in need of pharmacokinetic data.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePART I: Introduction\u003cbr\u003e \u003cbr\u003e THE DRUG DISCOVERY PROCESS\u003cbr\u003e Pharmacokinetics -\u003cbr\u003e Structure Relationship\u003cbr\u003e The Future of Small-Molecule Drugs\u003cbr\u003e \u003cbr\u003e LEAD OPTIMIZATION\u003cbr\u003e What Limits\/Reduces Oral Bioavailability?\u003cbr\u003e What Limits\/Reduces Plasma Half-Life?\u003cbr\u003e How to Improve bbb-Penetration?\u003cbr\u003e How to Avoid CYP Inhibition\/Induction?\u003cbr\u003e How to Avoid Interaction with the HumanEther-'a-go-go-Related Gene (hERG)?\u003cbr\u003e How to Prevent Toxicity?\u003cbr\u003e Examples of PK-Optimization in Animals\u003cbr\u003e \u003cbr\u003e PART II: The Pharmacokinetic Properties of Compound Classes\u003cbr\u003e \u003cbr\u003e ALKANES\u003cbr\u003e Metabolism\u003cbr\u003e \u003cbr\u003e ALKENES AND ALKYNES\u003cbr\u003e Metabolism\u003cbr\u003e \u003cbr\u003e ARENES\u003cbr\u003e Metabolism\u003cbr\u003e \u003cbr\u003e HALIDES\u003cbr\u003e Fluorine\u003cbr\u003e Chlorine\u003cbr\u003e Bromine\u003cbr\u003e Iodine\u003cbr\u003e Alkylating Agents\u003cbr\u003e \u003cbr\u003e AZIDES\u003cbr\u003e \u003cbr\u003e NITRO COMPOUNDS\u003cbr\u003e Metabolism\u003cbr\u003e \u003cbr\u003e AZO COMPOUNDS\u003cbr\u003e \u003cbr\u003e TRIAZENES\u003cbr\u003e \u003cbr\u003e NITRATES AND NITRITES\u003cbr\u003e \u003cbr\u003e N-NITROSO COMPOUNDS\u003cbr\u003e \u003cbr\u003e N-OXIDES\u003cbr\u003e \u003cbr\u003e ALCOHOLS\u003cbr\u003e Metabolism\u003cbr\u003e \u003cbr\u003e PHENOLS\u003cbr\u003e \u003cbr\u003e ETHERS\u003cbr\u003e Metabolism\u003cbr\u003e \u003cbr\u003e EPOXIDES\u003cbr\u003e \u003cbr\u003e PEROXIDES\u003cbr\u003e \u003cbr\u003e THIOLS\u003cbr\u003e \u003cbr\u003e THIOETHERS\u003cbr\u003e Metabolism\u003cbr\u003e \u003cbr\u003e SULFOXIDES\u003cbr\u003e \u003cbr\u003e SULFONES\u003cbr\u003e \u003cbr\u003e ALIPHATIC AMINES\u003cbr\u003e Basicity\u003cbr\u003e Metabolism\u003cbr\u003e Rates of N-Dealkylation\u003cbr\u003e \u003cbr\u003e QUATERNARY AMMONIUM SALTS\u003cbr\u003e \u003cbr\u003e AMIDINES\u003cbr\u003e \u003cbr\u003e GUANIDINES, ACYLGUANIDINES, AND BIGUANIDES\u003cbr\u003e \u003cbr\u003e Acylguanidines\u003cbr\u003e Biguanides\u003cbr\u003e \u003cbr\u003e ANILINES\u003cbr\u003e Metabolism\u003cbr\u003e \u003cbr\u003e HYDRAZINES, ACYLHYDRAZINES, AND HYDRAZONES\u003cbr\u003e \u003cbr\u003e ALDEHYDES\u003cbr\u003e \u003cbr\u003e KETONES\u003cbr\u003e \u003cbr\u003e CARBOXYLIC ACIDS\u003cbr\u003e Metabolism\u003cbr\u003e Bioisosteres of Carboxylic Acids\u003cbr\u003e Amino Carboxylic Acids, N-Acyl Amino Acids, and Related Compounds\u003cbr\u003e \u003cbr\u003e \u003cbr\u003e CARBOXYLIC ESTERS\u003cbr\u003e \u003cbr\u003e AMIDES\u003cbr\u003e \u003cbr\u003e LACTAMS AND IMIDES\u003cbr\u003e Pyrazolone Antipyretics\u003cbr\u003e Five-Membered Lactams as Nootropics\u003cbr\u003e \u003cbr\u003e NITRILES\u003cbr\u003e \u003cbr\u003e CARBONATES\u003cbr\u003e \u003cbr\u003e CARBAMATES\u003cbr\u003e Carbamates as Hypnotics\u003cbr\u003e \u003cbr\u003e UREAS\u003cbr\u003e \u003cbr\u003e THIOCARBONYL COMPOUNDS\u003cbr\u003e SULFONIC ACIDS\u003cbr\u003e \u003cbr\u003e SULFONIC ESTERS\u003cbr\u003e \u003cbr\u003e SULFATES AND SULFAMIC ACIDS\u003cbr\u003e \u003cbr\u003e PHOSPHONIC ACIDS\u003cbr\u003e \u003cbr\u003e PHOSPHORIC ACID DERIVATIVES\u003cbr\u003e \u003cbr\u003e N-(AMINOALKYL)BENZAMIDES, -BENZOATES, AND RELATED COMPOUNDS\u003cbr\u003e \u003cbr\u003e ARYLALKYLAMINES\u003cbr\u003e Antihistaminics: History\u003cbr\u003e \u003cbr\u003e PHENETHYLAMINES (2-PHENYLETHYLAMINES)\u003cbr\u003e Biological Activity of Phenethylamines\u003cbr\u003e Metabolism\u003cbr\u003e Tetrahydroisochinolines and Related Compounds\u003cbr\u003e \u003cbr\u003e AMINOALKYLINDOLES AND INDOLE ALKALOIDS\u003cbr\u003e \u003cbr\u003e PHENOTHIAZINES\u003cbr\u003e Metabolism\u003cbr\u003e \u003cbr\u003e DIBENZAZEPINES AND RELATED TRICYCLIC COMPOUNDS\u003cbr\u003e \u003cbr\u003e 3-ARYLOXY-2-HYDROXYPROPYLAMINES (B-ADRENERGIC ANTAGONISTS; 'B-BLOCKERS')\u003cbr\u003e Metabolism\u003cbr\u003e \u003cbr\u003e OPIATES\u003cbr\u003e \u003cbr\u003e N-(CARBOXYALKYL)-a-AMINO ACID AMIDES (PRILS)\u003cbr\u003e \u003cbr\u003e ANILIDES AND AMIDES OF GLYCINE\u003cbr\u003e \u003cbr\u003e PEPTIDES, PEPTIDOMIMETICS, AND RELATED OLIGOAMIDES\u003cbr\u003e Peptidomimetics\u003cbr\u003e Thrombin Inhibitors and Related Compounds\u003cbr\u003e \u003cbr\u003e OLIGOARYLAMINES, OLIGOARYLAMIDES, OLIGOARYLCARBAMATES, AND OLIGOARYLUREAS\u003cbr\u003e \u003cbr\u003e IMIDAZOLES\u003cbr\u003e \u003cbr\u003e TRIAZOLES\u003cbr\u003e \u003cbr\u003e PYRIDINES, PYRIMIDINES, AND RELATED COMPOUNDS\u003cbr\u003e Proton Pump Inhibitors\u003cbr\u003e \u003cbr\u003e QUINOLINES\u003cbr\u003e Tecans\u003cbr\u003e Quinazolines\u003cbr\u003e \u003cbr\u003e NUCLEOSIDE ANALOGS\u003cbr\u003e \u003cbr\u003e DIHYDROPYRIDINES\u003cbr\u003e \u003cbr\u003e ARENESULFONAMIDES\u003cbr\u003e Antibacterials\u003cbr\u003e Diuretics\u003cbr\u003e \u003cbr\u003e SULFONYLUREAS\u003cbr\u003e \u003cbr\u003e BENZODIAZEPINES\u003cbr\u003e \u003cbr\u003e STEROIDS\u003cbr\u003e \u003cbr\u003e ANTHRACYCLINES\u003cbr\u003e \u003cbr\u003e ARYLACETIC, BENZOIC, AND RELATED CARBOXYLIC ACIDS (NSAIDS)\u003cbr\u003e Salicylates\u003cbr\u003e \u003cbr\u003e QUINOLONECARBOXYLIC ACIDS (GYRASE INHIBITORS)\u003cbr\u003e \u003cbr\u003e B-LACTAMS\u003cbr\u003e Cephalosporins\u003cbr\u003e \u003cbr\u003e PROSTAGLANDIN ANALOGS\u003cbr\u003e \u003cbr\u003e SARTANS\u003cbr\u003e \u003cbr\u003e STATINS\u003cbr\u003e \u003cbr\u003e FOLIC ACID ANALOGS (ANTIFOLATES)\u003cbr\u003e \u003cbr\u003e TAXANES\u003cbr\u003e \u003cbr\u003e MACROCYCLIC COMPOUNDS","brand":"Wiley-VCH Verlag GmbH","offers":[{"title":"Default Title","offer_id":50579130483031,"sku":"9783527332267","price":138.65,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783527332267.jpg?v=1746101927","url":"https:\/\/bookcurl.com\/products\/lead-optimization-for-medicinal-chemists-pharmacokinetic-properties-of-functional-groups-and-organic-compounds-9783527332267","provider":"Book Curl","version":"1.0","type":"link"}